Navigation Links
Xcytrin in Medical News

Pharmacyclics Receives Non-Approvable Letter from the FDA for Xcytrin for the Treatment of Lung Cancer Brain Metastases

SUNNYVALE, Calif., Dec. 21 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. (Nasdaq: PCYC ) today announced that it has received a non-approvable letter from the U.S. Food and Drug Administration (FDA) for the company's new drug application (NDA) for Xcytrin(R) (motexafin gadolinium) Injection f...
Xcytrin in Medical Technology

Pharmacyclics Announces Promising Results From Phase 2 Clinical Trial of Xcytrin in Recurrent, Metastatic Non-Small Cell Lung Cancer

- Data Support Rationale for Comprehensive Ongoing Phase 2 Program as Combination Agent with Standard Chemotherapies and Pivotal Lung Cancer Trial Scheduled to Begin Early Next Year - CHICAGO and SUNNYVALE, Calif. June 01, 2007 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announced promisin...

Pharmacyclics Announces Interim Results From Two Ongoing Phase 2 Trials Supporting Potential of Xcytrin Plus Chemotherapy to Treat Recurrent Non-Small Cell Lung Cancer

WAILEA, Hawaii and SUNNYVALE, Calif., June 27, 2007 /PRNewswire-FirstCall/ -- Pharmacyclics, Inc. today announced preliminary results from two open-label, multi-center Phase 2 clinical trials supporting the potential use of Xcytrin(R) (motexafin gadolinium) Injection, the company's lead product ca...

Pharmacyclics Announces Presentations on Its Novel and Selective HDAC and Bruton's Tyrosine Kinase Inhibitor Compounds

...trin(R) (motexafin gadolinium) Injection, has completed Phase 3 clinical trials and several ongoing Phase 1 and Phase 2 clinical trials are evaluating xcytrin as a single agent or in combination with chemotherapy and/or radiation in multiple cancer types. More information about the company, its technology, a...

Pharmacyclics Identifies Functional Biomarkers for its Novel HDAC Inhibitor and Demonstrates Preclinical Anti-Tumor Activity with Bruton's Tyrosine Kinase Inhibitors

...trin(R) (motexafin gadolinium) Injection, has completed Phase 3 clinical trials and several ongoing Phase 1 and Phase 2 clinical trials are evaluating xcytrin as a single agent or in combination with chemotherapy and/or radiation in multiple cancer types. More information about the company, its technology, a...

Pharmacyclics Announces Presentations and Published Abstracts on Xcytrin at The 2007 American Society of Clinical Oncology Annual Meeting

...erapy: Preliminary results of Stage 1 About xcytrin Pharmacyclics is developing xcytrin as an anti-cancer agent with a novel mechanism of ...maging detectability, provides the opportunity for xcytrin to be used in a broad range of cancers. About Ph...
Other Tags
(Date:8/31/2015)... Knoxville, TN (PRWEB) , ... September 01, 2015 , ... ... function and other clinically relevant measures for physical therapy patients. The Registry is being ... President of FOTO, Inc. stated "We are happy to be selected to contribute FOTO ...
(Date:8/31/2015)... ... 31, 2015 , ... Cosmetic Town Journal is an online ... have a successful cosmetic procedure; from publishing encyclopedic medical articles to inform patients ... ready to help. , It is clear that the Cosmetic Town aesthetic surgery ...
(Date:8/31/2015)... ... ... to undergoing a hair transplant, most patients have donor hair moved from one part of ... on top of the scalp, as well as filling in areas missing hair, is a ... areas of their head. , What about patients who have a limited, or even depleted, ...
(Date:8/31/2015)... ... August 31, 2015 , ... The Lisle family law firm ... Scott has been nominated by his peers to earn a “Leading Lawyers” distinction. ... of attorneys in the state of Illinois. The nomination process is based on statewide ...
(Date:8/31/2015)... ... August 31, 2015 , ... CareSource, a nonprofit Ohio-based ... In this capacity, Michael will provide strategic leadership for CareSource’s marketing, branding, corporate ... programs that have contributed to the company’s rapid growth. As the CareSource business ...
Breaking Medicine News(10 mins):Health News:FOTO Selected as Official Registry Partner with Physical Therapy Outcomes Registry 2Health News:Cosmetic Town: A One Stop Plastic Surgery Community 2Health News:Body Hair Transplants to Help Achieve a Full Head of Hair 2Health News:DuPage County Family Law Attorney Named Illinois Leading Lawyer 2Health News:CareSource Names Vice President, Marketing and Corporate Communications 2
(Date:8/20/2015)... ., Aug. 20, 2015 NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce market ... has joined The Smart Card Alliance and the EMV ... Alliance and the Smart Card Alliance Latin America (SCALA) ... industry peers and thought leaders promoting adoption of smart ...
(Date:8/12/2015)... Aug. 12, 2015   MedNet Solutions , an ... spectrum of clinical research, is proud to announce that ... comprehensive SaaS-based eClinical technology platform, has led the way ... two quarters of 2015.   Q2 2015 and Q1 ... measured by contract value sold in the company,s 15 ...
(Date:8/10/2015)... TELTOW, Germany , August 10, 2015 ... a world leader in Eye Tracking Technology for more ... OEM Eye Tracking Platform for integration into all consumer ... reference designs for seamless integration of eye tracking into ... HMDs and augmented reality smart glasses. Omnivision,s leading sensor ...
Breaking Biology News(10 mins):NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 2SMI Completes OEM Eye Tracking Platform to Cover All Consumer Displays 3
Other Contents